NCT02211144已完成1 期
Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered Twice Daily Orally (Total Daily Dose 90, 120, 150 or 180 mg) to Healthy Human Subjects for 14 Days. A Placebo-controlled, Dose Escalation Study Double Blinded at Each Dose Level
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 120
- 主要终点
- Number of patients with clinical relevant findings in electrocardiogram (ECG)
研究概览
简要总结
Study to assess the safety and pharmacokinetics of BIRB 796 BS tablets administered as multiple daily doses at various dose levels
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 60 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male or female subjects as determined by results of screening
- •Signed written informed consent in accordance with Good Clinical Practice (GCP) and local legislation
- •Female subjects who were not lactating and not of child bearing potential as defined by surgically sterile or post menopausal (no periods for at least 12 months and elevated follicle stimulating hormone (FSH) with low estradiol while on no estrogen supplementation). Females were to use barrier contraception (e.g. condoms) prior to administration of study medication, during the study and at least one month after release from the study. Women must have had negative blood pregnancy tests
- •Age ≥ 18 and ≤ 60 years
- •Body mass index (BMI) ≥ 18.5 and ≤ 29.9 kg/m2
- •Able to communicate well with the investigator and to comply with study requirements
- •Laboratory values within a clinically defined reference range
排除标准
- •Any finding of the medical examination (including blood pressure, pulse rate, and electrocardiogram) deviating from normal and of clinical relevance
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunologic or hormonal disorders
- •Surgery of gastrointestinal tract (except appendectomy)
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of orthostatic hypotension, fainting spells or blackouts
- •Chronic or relevant acute infections
- •History of allergy/hypersensitivity (including drug allergy) which is deemed relevant to the trial as judged by the investigator
- •History of vasculitis (past history of fever, malaise, myalgias, rash, etc.)
- •Intake of drugs with a long half-life (> 24 hours) (< 1 month prior to administration or during the trial)
- •Use of any drugs, which might influence the results of the trial, (< 10 days prior to administration or during the trial)
- •Participation in another trial with an investigational drug (< 1 months prior to administration (at least 10 times the relevant elimination half-life) or during the trial)
- •Having had prescription medication 2 weeks prior to study drug administration or over the counter medication 1 week prior to study drug administration (at least 10 times the relevant elimination half-life)
- •Alcohol abuse (> 60 g/day)
- •Drug abuse
- •Use of methylxanthine-containing drinks or foods (coffee, tea, cola, energy drinks, chocolate, etc.), grapefruit or grapefruit juice, alcohol, green tea, or tobacco < 5 days prior to administration of study drug
- •Blood donation or loss > 400 mL (< 1 month prior to administration or during the trial)
- •Excessive physical activities (< 5 days prior to administration or during the trial)
- •Following specific laboratory findings: white blood cell count, C-reactive protein, gamma-glutamyl-transferase, aspartate transaminase, alanine transaminase, or glutamate dehydrogenase above the normal range; any erythrocytes or > 15 mg/dl protein on urine dipstick if not menstruating
- •Any EKG value outside of the reference range of clinical relevance including, but not limited to QTcB > 480 ms or QRS interval > 110 ms
- •History of any familial bleeding disorder
- •Inability to comply with dietary regimen of study centre
- •Inability to comply with investigator's instructions
研究组 & 干预措施
BIRB 796 BS
Experimental
in escalating doses
干预措施: BIBR 796 BS (Drug)
BIRB 796 BS
Experimental
in escalating doses
干预措施: Placebo (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Number of patients with clinical relevant findings in electrocardiogram (ECG)
时间窗: up to day 21
Number of patients with clinically relevant changes in laboratory parameters
时间窗: up to day 21
Number of patients with adverse events
时间窗: up to 35 days
Number of patients with clinically significant changes in vital signs (pulse rate, systolic and diastolic blood pressure)
时间窗: up to day 21
Clinical assessment of tolerability on a 4-point scale
时间窗: day 21
次要结局
- Elimination half-life (t1/2)(up to day 16)
- Terminal elimination rate constant (λz)(up to day 16)
- Apparent volume of distribution based on terminal elimination phase, divided by F (bioavailability factor) (Vz/F)(up to day 16)
- Maximum observed plasma concentration during steady state dosing interval (Cmax,ss)(up to day 16)
- Time to the maximum plasma concentration at steady state (tmax,ss)(up to day 16)
- Average steady state plasma concentration (Css)(up to day 16)
- Total apparent oral clearance of drug from plasma after oral administration (CL/F )(up to day 16)
- area under the plasma concentration versus time curve at different time points (AUC)(up to day 16)
- Mean residence time (MRT)(up to day 16)
- Morning trough plasma concentration prior day 14(on day 2, 3, 5, 7, 9, 13 and 14)
研究者
相似试验
已完成
1 期
Safety and Pharmacokinetics of BIRB 796 BS Tablets Administered to Healthy Human SubjectsHealthyNCT02209805Boehringer Ingelheim49
已完成
1 期
Safety, Pharmacokinetics and Pharmacodynamics of BIRB 796 BS Tablets Administered to Healthy Human SubjectsHealthyNCT02211157Boehringer Ingelheim24
已完成
1 期
Safety, Pharmacokinetics and Pharmacodynamics of Single Rising Doses Oral BIRB 796 BS in Healthy Human SubjectsHealthyNCT02208856Boehringer Ingelheim64
已完成
2 期
BIRB 796 BS Versus Placebo in Patients With Moderate to Severs Plaque-type PsoriasisPsoriasisNCT02209753Boehringer Ingelheim182
已完成
1 期
Safety, Tolerability, and Pharmacokinetics of Single Rising Oral Doses of BIRB 1017 BS as a Solution in PEG 400 / 26% Ethanol Administered to Healthy Male SubjectsHealthyNCT02184338Boehringer Ingelheim48